| Business Summary | | Lescarden,
Inc.
is
engaged
in
the
research,
testing
and
development
of
medications
for
the
control
and
cure
of
various
diseases
and
the
licensing
of
its
technologies
for
commercialization
by
other
companies.
The
Company's
product
developments
continue
to
concentrate
on
its
proprietary
materials,
Catrix
and
POLY-NAG,
both
in
terms
of
their
therapeutic,
cosmetic
and
food
supplement
values.
The
Company
is
focusing
a
significant
portion
of
its
resources
on
the
development
of
a
complete
marketing
program
for
pure
Catrix
powder,
as
well
as
Catrix
Ointment,
creams
and
lip
balm,
in
the
treatment
of
a
multiplicity
of
topical
wounds.
Additionally,
the
Company
has
pursued
a
program
to
establish
the
clinical
efficacy
of
its
POLY-NAG
material
as
an
anti-arthritic.
The
product
is
derived
from
specially
processed
crustacean
shells
(Poly-N-Acetyl-Glucosamine). | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | LCAR
is
engaged
in
research,
testing,
and
development
of
medications
for
the
control
and
cure
of
various
diseases
and
the
licencing
of
its
technologies
by
other
companies.
LCAR
has
discovered
and
is
primarily
investigating
Catrix(R).
For
the
fiscal
year
ended
5/31/01,
revenues
fell
91%
to
$41
thousand.
Net
loss
fell
6%
to
$568
thousand.
Revenues
reflect
the
absence
of
license
fees
earned.
Lower
loss
reflects
a
decrease
in
cost
of
sales. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Gerard Dupuis, 62 Pres,
CEO, Chairman, Gen. Counsel and Sec.. | $150K | Charles Maxwell, 68 Director
and Exec. VP | -- | William Sherman, Ph.D., 58 Exec.
VP for Science Elect of the Company | -- | Dollar amounts are as of 31-May-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|